Financial Review: Vivani Medical (NASDAQ:VANI) & NeurAxis (NASDAQ:NRXS)

Vivani Medical (NASDAQ:VANI) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Insider and Institutional Ownership

6.8% of Vivani Medical shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 44.3% of Vivani Medical shares are held by insiders. Comparatively, 15.2% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vivani Medical and NeurAxis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$25.65 million	($0.45)	-2.56
NeurAxis	$2.46 million	7.08	-$14.63 million	($1.84)	-1.32

NeurAxis has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vivani Medical and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-102.42%	-49.21%
NeurAxis	-492.76%	N/A	-641.25%

Analyst Ratings

This is a summary of current recommendations and price targets for Vivani Medical and NeurAxis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	0	0	1	0	3.00
NeurAxis	0	0	0	0	0.00

Vivani Medical currently has a consensus target price of $3.00, indicating a potential upside of 160.87%. Given Vivani Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Vivani Medical is more favorable than NeurAxis.

Volatility & Risk

Vivani Medical has a beta of 3.22, indicating that its stock price is 222% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 4.22, indicating that its stock price is 322% more volatile than the S&P 500.

Summary

Vivani Medical beats NeurAxis on 7 of the 13 factors compared between the two stocks.

About Vivani Medical

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.